A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
PainPeripheral Neuropathy
Interventions
DRUG

Sativex®

Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours

DRUG

Placebo

containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient

Trial Locations (1)

B91 2JL,

Pain Management Research, Clinical Trials Unit, Netherwood House, Solihull Hospital, Solihull

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY